Nanomedicine: Redefining Cancer Therapy
Sapu Bioscience and Oncotelic are pioneering sub-20 nm Deciparticle™ technology— transforming drug molecules into programmable biological entities.
From Concept to Clinic
Our proprietary Deciparticle™ platform enables precise delivery of water-insoluble drugs by engineering ultrasmall nanoparticles (<20 nm) that behave like molecular drugs—evading immune detection, penetrating tumors, and improving bioavailability.
With a 90% success rate across over 100 tested APIs, Deciparticle™ nanomedicine accelerates IND timelines and enables next-generation cytotoxic formulations.
To provide broader context, our team published a comprehensive review in the International Journal of Molecular Sciences (IJMS) covering 5–15 nm nanoparticles (600+ references), mapping the broader scientific landscape and explaining why this ultrasmall size window is attractive for platforms like Deciparticle™ and programs such as Sapu-003 ( https://doi.org/10.3390/ijms262210842 ).
Evolution of Nanomedicine
2005 — Abraxane®
The first nanoparticle chemotherapy for solid tumors, co-invented by Dr. Vuong Trieu. Established the foundation for albumin-bound nanomedicine.
2010 — Cynviloq™
Next-generation Abraxane developed via IgDraSol using polymeric micelles instead of albumin, achieving bioequivalence under 505(b)(2) pathway.
2025 — Sapu-003
Fourth-generation Deciparticle™ everolimus delivering 100% bioavailability and converting cytostatic to cytotoxic efficacy through dual mTORC inhibition.
Sapu-003: Intravenous Everolimus Deciparticle
Sapu-003 transforms everolimus, a widely used oral mTOR inhibitor, into an intravenous Deciparticle™ formulation with 100% bioavailability, superior tissue penetration, and significantly reduced systemic toxicity.
- Dual mTORC1 + mTORC2 inhibition
- Weekly dosing improves T-cell recovery and immune response
- Reduced mucositis, pneumonitis, and cytopenia
- Synergistic with metformin and statins for metabolic escape blockade
Manufacturing Excellence
The Sapu San Diego GMP Facility is the first permitted Deciparticle™ manufacturing site for lyophilized injectable antineoplastic products, with a capacity of six clinical-grade products per year.
One-pot synthesis → Fill-finish → Lyophilization.
Collaborative Path to Phase I
-
GMP Manufacturing:
Sapu Bioscience (San Diego, CA)
-
IND Enabling Studies:
Medicilon Group
-
CRO Partner:
iNGENū CRO
-
Clinical Partner:
SOCRU